CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 870 enrolled
Drug / intervention
Clopidogrel tablet +1 moredrug
Likely dose
Cilostazol 100 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06242132
NCT06242132Phase 3Completed

Clopidogrel Versus Cilostazol in Ischemic Stroke, a Randomized Controlled Trial

Kafrelsheikh University·interventional·Posted Feb 5, 2024·Updated Sep 19, 2024

In Brief

A Phase 3 clinical trial evaluating Clopidogrel tablet and Cilostazol 100 MG for Ischemic Stroke. Completed, enrolled 870 participants across 1 site.

Detailed Summary

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of clopidogrel administered within 24 hours of the first-ever moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedFeb 5, 2024
Enrollment StartJun 1, 2022
Primary CompletionJul 1, 2024
Study CompletionAug 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 2.4 years ago

Interventions

Clopidogrel tabletdrug

Efficacy and safety of a 300mg loading dose of clopidogrel administered within 24 hours of first-ever ischemic stroke followed by 75mg daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.

Cilostazol 100 MGdrug

Efficacy and safety of 200 mg cilostazole followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.